Novo Nordisk is shifting toward external contract manufacturing for its oral peptide treatments to meet rising global demand. Analysts at Macquarie have highlighted Divi's Laboratories as a potential beneficiary due to its vertical integration, though no official partnership has been announced.
Novo Nordisk is changing its manufacturing strategy to handle the high demand for its oral peptide treatments. The global pharmaceutical company, known for its diabetes and weight-loss drugs, is increasingly looking to external partners, known as Contract Development and Manufacturing Organizations (CDMOs), to produce the necessary peptide Active Pharmaceutical Ingredients (APIs). This shift is necessary because oral drugs require a significantly higher amount of API compared to injectable versions—in some cases, up to 73 times more.
This strategic pivot has drawn investor interest toward Indian pharmaceutical companies, with analysts at Macquarie identifying Divi's Laboratories as a potential key partner. The focus on Divi’s stems from its established vertical integration, which allows the company to produce many of its own raw materials. This setup can provide better control over supply chains, quality, and costs, which are critical requirements for Novo Nordisk’s vendor selection process.
Investors should note that there is no confirmed partnership between Novo Nordisk and Divi’s Laboratories as of October 5, 2026. The current interest is based on analyst expectations that the Indian company’s existing infrastructure for synthetic peptides aligns well with the scale required by global drugmakers. While the prospect of securing such a high-volume client is significant, any potential collaboration remains speculative until the companies themselves provide official confirmation through exchange filings.
Divi’s Laboratories recently demonstrated strong financial performance, reporting a consolidated net profit of Rs 902 crore for the first quarter of the 2027 fiscal year, a 65.5% increase compared to the previous year. As of October 5, 2026, the stock was trading around Rs 9,160. The company has officially closed its trading window for designated persons, a standard practice ahead of the upcoming declaration of its second-quarter financial results.
While the industry outlook for peptide manufacturing is expanding, investors must consider the challenges involved. Success in this specialized field depends heavily on the ability to scale up complex custom synthesis projects without delays. Furthermore, the pharmaceutical manufacturing industry is subject to strict regulatory oversight, and any compliance issues at manufacturing sites can disrupt operations and growth. Divi’s also faces global competition, with major players like WuXi AppTec and Samsung Biologics also vying for a share of the growing peptide therapeutic market. Future investor attention will likely center on the company’s upcoming quarterly management commentary and any official announcements regarding new large-scale custom synthesis contracts.